Literature DB >> 32827755

Long noncoding RNAs in cancer immunity: a new avenue in drug discovery.

Anindya Dutta1, Ananya Roy1, Subhrangsu Chatterjee2.   

Abstract

The central role of the nonprotein-coding portion of the genome, such as long noncoding (lnc)RNAs is emerging as a hidden player manipulating the immune system in cancer. lncRNAs, in association with their interacting partners, regulate the expression of various immune system genes, which are perturbed during cancer. The tissue-specific expression of lncRNAs and their importance in cellular proliferation, the tumor microenvironment (TME), epithelial-mesenchymal transition (EMT), and modulation of the cells of the innate and adaptive immune system have novel therapeutic implications in establishing lncRNAs as biomarkers and targets to overcome cancer-associated immunosuppression. In this review, we establish and strengthen the link between lncRNAs and cancer immunity.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32827755     DOI: 10.1016/j.drudis.2020.07.026

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  2 in total

1.  Rhophilin rho GTPase binding protein 1-antisense RNA 1 (RHPN1-AS1) promotes ovarian carcinogenesis by sponging microRNA-485-5p and releasing DNA topoisomerase II alpha (TOP2A).

Authors:  Yi Zhou; Jing Li; Xiaoxin Yang; Yu Song; Haigang Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

2.  LncRNA ST8SIA6-AS1 Promotes Cholangiocarcinoma Progression by Suppressing the miR-145-5p/MAL2 Axis.

Authors:  Junchuang He; Hongxian Yan; Sidong Wei; Guoyong Chen
Journal:  Onco Targets Ther       Date:  2021-05-17       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.